JAMA Oncology @JAMAOnc Twitter profile

Last Seen Profiles

@Secabo13__

@jordanwerth23

@stw46

@thatmouthybroad

@NLEOMF

@Carter418080520

@GetLocoNow

@CCAADB

@patriota0703

@zerocalbanana

@HailStateMKTG

@NinaKnight37412

@nicole_ada53912

@BlizzxrdR6

@nerimonmon

@JWeber_FB

@worshipRoxx

@HamarikyuGarden

@MMGACIC

@ICastroI

@wis771

@Clubnanas

@traigoeldiablo

@Kirmit_Arielle

@Silifkeli1960

@MNP_Secretariat

@HaMokedRights

@KittyKartRacing

@tvpc8

@HercsyLive

@Pecintastw4050

@LexisKingWWE

@AlanieOmer

@McconicoTazz

@GodysseyPodcast

@Meanless_eth

JAMA Oncology

@JAMAOnc

7 months

This study found that women with breast cancer who used vaginal estrogen therapy (vaginal creams or vaginal tablets), compared with no hormone replacement therapy use, did not appear to have an increased risk of early breast cancer-specific mortality.

Vaginal Estrogen Therapy Use and Survival in Breast Cancer

This cohort study compares the mortality risk associated with vaginal estrogen therapy vs no hormone replacement therapy in 2 cohorts of patients with breast cancer in Scotland and Wales.

jamanetwork.com

11

216

527

JAMA Oncology

@JAMAOnc

2 months

Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval. #AACR24

12

126

291

JAMA Oncology

@JAMAOnc

1 year

This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment.

4

81

227

JAMA Oncology

@JAMAOnc

2 years

This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment.

7

74

214

JAMA Oncology

@JAMAOnc

6 years

Patients who pursued #ComplementaryMedicine for breast, prostate, colon or lung cancer had a significantly worse overall survival, likely explained by delays in or refusal to pursue conventional #cancer therapies @sky__john @cpgYALE @YaleCOPPER @jamesbyu

5

256

212

JAMA Oncology

@JAMAOnc

6 years

You send plasma from same patient for cell-free DNA testing to two different companies. In nearly all cases, you get different results from each. Data offer humbling reminder of imprecision of #PrecisionMedicine .

5

178

194

JAMA Oncology

@JAMAOnc

14 days

After accounting for biases and confounders, cancer clinical trial participation was not associated with longer survival.

3

70

174

JAMA Oncology

@JAMAOnc

5 years

Comprehensive meta-analysis of 125 trials treating w anti-PD-1 & anti-PD-L1 inhibitors across a broad range of cancers reveals patterns of observed toxicities & significant differences among different checkpoint inhibitors #immunotherapy

4

113

150

JAMA Oncology

@JAMAOnc

7 months

In this study, giving an antibody-drug conjugates (T-DXd, T-DM1, SG) concurrently with stereotactic radiotherapy was associated w/ higher risk of radiation necrosis. The absolute risk was low for small lesions, but increased rapidly w/ volume & prior RT.

2

60

148

JAMA Oncology

@JAMAOnc

5 years

Learn about measuring and comparing #cancer treatment in practice: clinical trials, end points, and #statistics

1

77

148

JAMA Oncology

@JAMAOnc

4 years

An international multicenter analysis, FIRE-SCLC, reports encouraging outcomes with first-line stereotactic radiosurgery (SRS) for brain metastases from small-cell #lungcancer , with no decline in overall survival compared to whole-brain radiation (WBRT)

3

69

135

JAMA Oncology

@JAMAOnc

5 years

High tumor mutational burden is associated with immune-related adverse events during anti-PD-1 therapy across multiple cancer types #immunotherapy

2

66

133

JAMA Oncology

@JAMAOnc

6 years

You send plasma from same patient for cell-free DNA testing to two different companies. In nearly all cases, you get different results from each. Data offer humbling reminder of imprecision of #PrecisionMedicine .

5

127

132

JAMA Oncology

@JAMAOnc

8 months

What is a geriatric assessment & why is it an important but under-utilized tool for older patients with cancer? This JAMA Oncology Patient Page explains its value.

1

74

133

JAMA Oncology

@JAMAOnc

3 months

Neoadjuvant pembrolizumab plus carboplatin and docetaxel showed a pathologic complete response rate of 58% and a 3-year event-free survival of 86% in patients with triple-negative breast cancer.

1

48

132

JAMA Oncology

@JAMAOnc

5 years

In the first RCT to date, adding metformin to standard EGFR-TKI treatment for NSCLC significantly increases PFS and OS w/o added toxicity

3

59

130

JAMA Oncology

@JAMAOnc

8 months

Phase 2 trial of immune checkpoint inhibitor alone or combined w/ stereotactic body radiation therapy (SBRT) for patients w/ locally adv or metastatic solid tumors, adding SBRT did not significantly improve progression-free or overall survival. #RadOnc

1

42

131

JAMA Oncology

@JAMAOnc

3 years

Phase III randomized study evaluated the role of internal mammary node irradiation (IMNI) in node-positive #breastcancer . IMNI did not improve the DFS in unselected patients, but did improve DFS in patients with medially or centrally located tumors

0

72

129

JAMA Oncology

@JAMAOnc

5 years

Female oncologists attend fewer conferences than males; should societies facilitate childcare to help ensure broader participation?

Association of Gender and Parenthood With Conference Attendance Among Early Career Oncologists

This survey study evaluates the association of gender and parenthood status with conference attendance among career oncologists.

jamanetwork.com

8

40

128

JAMA Oncology

@JAMAOnc

2 months

Most viewed in the last 7 days from @JAMAOnc : Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemoimmunotherapy?

2

29

125

JAMA Oncology

@JAMAOnc

4 months

This study found that women with breast cancer who used vaginal estrogen therapy (vaginal creams or vaginal tablets), compared with no hormone replacement therapy use, did not appear to have an increased risk of early breast cancer-specific mortality.

Vaginal Estrogen Therapy Use and Survival in Breast Cancer

This cohort study compares the mortality risk associated with vaginal estrogen therapy vs no hormone replacement therapy in 2 cohorts of patients with breast cancer in Scotland and Wales.

jamanetwork.com

2

58

120

JAMA Oncology

@JAMAOnc

11 months

Randomized trial of intermittent hormone therapy +/- radiation to oligometastatic sites of #prostatecancer shows significantly improved PFS & assoc time off hormone therapy & w/normal testosterone from combination. #RadOnc #PCSM #GUCSM

Addition of MDT to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer

This randomized clinical trial examines whether the addition of metastasis-directed therapy (MDT) to intermittent hormone therapy in men with oligometastatic prostate cancer improves progression-free...

jamanetwork.com

3

48

117

JAMA Oncology

@JAMAOnc

6 years

Sending plasma from same patient to 2 different labs for cell-free DNA testing shows humbling low concordance in vast majority of cases. Implications limit reliability of #PrecisionMedicine .

3

97

115

JAMA Oncology

@JAMAOnc

6 years

You send plasma from same patient for cell-free DNA testing to two different companies. In nearly all cases, you get different results from each. Data offer humbling reminder of imprecision of #PrecisionMedicine .

5

99

111

JAMA Oncology

@JAMAOnc

2 years

Interview with Linda M. Liau, MD, PhD, author of Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma, in a podcast with @JackWestMD .

0

32

111

JAMA Oncology

@JAMAOnc

6 months

Neoadjuvant pembrolizumab plus carboplatin and docetaxel showed a pathologic complete response rate of 58% and a 3-year event-free survival of 86% in patients with triple-negative breast cancer.

0

38

113

JAMA Oncology

@JAMAOnc

7 years

Chimeric antigen receptor (CAR) T-cell therapy for #cancer : an explanation for patients.

0

86

107

JAMA Oncology

@JAMAOnc

6 years

This Patient Page defines some of the important terms and techniques that #cancer researchers use to measure and report their findings.

0

70

108

JAMA Oncology

@JAMAOnc

5 years

In the first RCT to date, adding metformin to standard EGFR-TKI treatment for NSCLC significantly increases PFS and OS w/o added toxicity #LCSM

Metformin Plus TKIs Compared With TKIs Alone in Patients With EGFR-Mutated Lung Adenocarcinoma

This randomized clinical trial assesses the progression-free survival in patients with advanced lung adenocarcinoma who received treatment with epidermal growth factor receptor tyrosine kinase...

jamanetwork.com

3

57

104

JAMA Oncology

@JAMAOnc

5 years

DNA polymerase epsilon (POLE) and delta (POLD) mutations are found to be new predictive biomarkers for immunotherapy across multiple cancer types

3

61

106

JAMA Oncology

@JAMAOnc

1 year

Randomized clinical trial shows machine learning mortality predictions & behavioral nudges to cancer clinicians led to significant increase in rate of serious illness conversations & altered outcomes of end-of-life care for pts w/cancer. #HPM #EOL

1

24

106

JAMA Oncology

@JAMAOnc

3 months

ICI-chemotherapy did not improve survival compared with ICI alone in older adults with previously untreated advanced NSCLC, but increased the incidence of grade 3 and higher immune-related adverse events.

2

34

103

JAMA Oncology

@JAMAOnc

5 years

NCI Data Science Lab shows combination of CD8+ T-cell, mutational burden and PD1 expression predicts anti-PD1/PDL1 response across multiple tumors

0

48

99

JAMA Oncology

@JAMAOnc

3 years

High-intensity aerobic exercise improves cardiorespiratory fitness and may suppress the biochemical progression of #prostatecancer in the active surveillance setting #PCSM #GUCSM #ActiveSurveillance #ExerciseOncology

1

36

99

JAMA Oncology

@JAMAOnc

5 years

#Exercise has significant promise to improve #cancer outcomes. Early phase trials are required to guide the successful design of definitive testing.

0

45

95

JAMA Oncology

@JAMAOnc

6 years

Did You Know? New studies indicate that the gut #microbiome can influence the effectiveness of #cancer immunotherapy and manipulating gut bacteria might expand the population of patients who benefit from treatment #PD1Inhibitors

2

64

91

JAMA Oncology

@JAMAOnc

4 years

0

37

93

JAMA Oncology

@JAMAOnc

6 months

What is a geriatric assessment & why is it an important but under-utilized tool for older patients with cancer? This JAMA Oncology Patient Page explains its value.

0

56

92

JAMA Oncology

@JAMAOnc

2 months

34% of patients with advanced cancer and 29% of caregivers prioritize symptom management over life extension. Interventions to target prognostic awareness & reduce discordant goals of care can help develop realistic expectations.

End-of-Life Care Goals Among Patients With Advanced Cancer and Their Caregivers

This cohort study investigates the patterns of goals of care among patients with advanced cancer and their family caregivers over the last years of the patient’s life and the associations of goals...

jamanetwork.com

2

29

94

JAMA Oncology

@JAMAOnc

1 month

In patients with node-positive breast cancer, axillary recurrence after omission of axillary lymph node dissection was rare with no difference by type of surgery (sentinel lymph node biopsy with dual-tracer mapping vs targeted axillary dissection).

1

40

93

JAMA Oncology

@JAMAOnc

7 years

Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors

0

69

88

JAMA Oncology

@JAMAOnc

4 years

KEYNOTE-062 trial in loc adv gastric/GE jxn cancer shows 1st line pembrolizumab is non-inf to chemo w greater tx effect in pts w/MSI-H or high PD-L1 expression (CPS >10) & no meaningful benefit of pembro+chemo observed @KoheiShitara #GICSM #VisualAbstract

11

46

88

JAMA Oncology

@JAMAOnc

3 years

In PARSIFAL, fulvestrant–palbociclib did not improve PFS vs letrozole–palbociclib as first-line treatment for endocrine-sensitive, HR–positive/HER2-negative advanced breast cancer. Letrozole is confirmed as the preferred palbociclib partner in this setting

0

28

89

JAMA Oncology

@JAMAOnc

6 years

Did You Know? New studies indicate that the gut #microbiome can influence the effectiveness of #cancer immunotherapy and manipulating gut bacteria might expand the population of patients who benefit from treatment #PD1Inhibitors

1

63

87

JAMA Oncology

@JAMAOnc

3 months

Hypofractionated postprostatectomy radiotherapy (HYPORT) is noninferior to conventionally fractionated postprostatectomy (COPORT) in terms of patient-reported late toxic effects and is a new acceptable practice standard. @NRGOnc

5

39

88

JAMA Oncology

@JAMAOnc

10 months

In PERNETTA trial, 210 pts with HER2 positive metastatic breast cancer were randomized to pertuzumab & trastuzumab with or without chemotherapy. OS was similar for both strategies despite a longer PFS observed w/ the addition of chemo to dual blockade.

1

37

87

JAMA Oncology

@JAMAOnc

1 year

Phase 3 randomized clinical trial of 156 pts w/ #ProstateCancer shows MRI guidance of stereotactic body radiotherapy(SBRT) showed significantly reduced acute moderate genitourinary & GI toxic effects vs. CT guidance. #GUCSM #PCSM #RadOnc

1

30

86

JAMA Oncology

@JAMAOnc

6 years

Unlike response rate, which correlates poorly w overall surv (OS) on trials of #immunotherapy in many #tumor types, PFS at 6 months correlates well w OS, far better surrogate endpoint.

2

65

86

JAMA Oncology

@JAMAOnc

4 years

0

42

86

JAMA Oncology

@JAMAOnc

4 months

Results of this randomized clinical trial suggest that after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma, radiotherapy alone was noninferior to chemoradiotherapy in terms of 3-year progression-free survival.

5

29

85

JAMA Oncology

@JAMAOnc

2 months

Neoadjuvant chemo-immunotherapy is superior to neoadjuvant chemotherapy across surgical, pathological and efficacy outcomes for patients with resectable NSCLC and improves EFS in patients with tumor PD-L1 <1%. @sorin_mark @DoctorJSpicer

Neoadjuvant Chemoimmunotherapy for NSCLC

This meta-analysis investigates the association of neoadjuvant chemoimmunotherapy with patient benefits vs neoadjuvant chemotherapy in patients with non–small cell lung cancer (NSCLC).

jamanetwork.com

2

31

85

JAMA Oncology

@JAMAOnc

4 years

Randomised trial supporting consolidation RT in chemoresponsive NPC as the new SOC @DrMLChua #VisualAbstract #radiotherapy #nasopharyngealcarcinoma #metastasis

1

49

85

JAMA Oncology

@JAMAOnc

2 years

This review aims to highlight the current understanding of the association of the gut microbiome with the therapeutic response to immunotherapy, chemotherapy, radiotherapy, cancer surgery and more.

1

46

84

JAMA Oncology

@JAMAOnc

1 year

Study of patients with #NSCLC showed no survival difference between 2-yr fixed duration vs indefinite #immunotherapy , suggesting that IO can be d/c at 2 yrs. @PennCancer @flatironhealth @lovasunMD @Ron_cology @CharuAggarwalMD #ASCO23

0

38

83

JAMA Oncology

@JAMAOnc

5 years

#Palliativecare is associated with improved survival in patients with advanced #lungcancer @DSullyResearch @OHSUNews @vaportland @OHSUKnight

0

44

81

JAMA Oncology

@JAMAOnc

4 years

SABR for spinal mets—the need-to-know points for the modern oncologist. A novel, effective and personalized approach #SABR #cancer

1

40

78

JAMA Oncology

@JAMAOnc

2 months

Using ePROs to prompt direct patient trial invitations resulted in greater enrollment to a symptom-intervention trial than standard of care physician-based referral. @nick_verdini @JunMaoMD @ErinGillespieMD @MSK_RadOnc

2

30

80

JAMA Oncology

@JAMAOnc

7 years

Going With the Flow: The Promise and Challenge of Liquid Biopsies

0

58

79

JAMA Oncology

@JAMAOnc

2 years

Randomized clinical trial finds administration of gonadotropin-releasing hormone analogs (GnRHa) with chemotherapy in premenopausal pts with #BreastCancer reduces risk of premature ovarian insufficiency ( #POI ) and promotes recovery of ovarian function.

0

30

81

JAMA Oncology

@JAMAOnc

5 years

Can pts who develop immune-related adverse events (AEs) on PD-1 or PD-L1 inhibitor immunotherapy be re-challenged later? Cohort of 93 pts from @GustaveRoussy tested, w 55% developing AEs w 2nd administration, typically less severe than 1st exposure

3

46

77

JAMA Oncology

@JAMAOnc

7 months

RNA sequencing provides an opportunity to more accurately identify individuals with hereditary cancer susceptibility by increasing detection and improving classification of disease-causing variants in cancer susceptibility genes. #ASHG23

1

34

79

JAMA Oncology

@JAMAOnc

1 year

Study shows incidence of suicide among pts undergoing cancer operations was significantly elevated compared to general population, highlighting need for programs to actively implement regular suicide screening among such pts

Incidence, Timing, and Factors Associated With Suicide Among Patients Undergoing Surgery for Cancer

This cohort study evaluates the incidence, timing, and factors associated with suicide among patients undergoing cancer operations compared with the general US population.

jamanetwork.com

4

40

79

JAMA Oncology

@JAMAOnc

1 month

ICI-chemotherapy did not improve survival compared with ICI alone in older adults with previously untreated advanced NSCLC, but increased the incidence of grade 3 and higher immune-related adverse events.

0

30

79

JAMA Oncology

@JAMAOnc

6 years

Circulating tumor cells ( #CTCs ) on a single blood test about 5 years after diagnosis of high risk hormone receptor-positive #BreastCancer has significant prognostic value, with a 13.1-fold higher risk for late recurrence. #BCSM

1

55

74

JAMA Oncology

@JAMAOnc

4 months

Breast cancer incidence rates among women aged 20-49 is increasing, driven by increases in ER+ tumors. Prevention efforts in young women need to adopt a targeted approach to address racial disparities in incidence rates.

1

33

75

JAMA Oncology

@JAMAOnc

4 years

This patient page on chemotherapy-induced peripheral #neuropathy ( #CIPN ) reviews risks, prevention, symptoms, and management of this common and challenging complication of #cancer treatment. #ThrowbackThursday

2

38

76

JAMA Oncology

@JAMAOnc

3 years

TROG SAFRON II - 90 pt RCT of 28Gy single (SF) vs 4x12Gy multifraction SABR for 1-3 oligometastases to lung. No difference in toxicity, local control, survival, relapse, or QoL. SF is a good candidate for escalation to future RCTs

1

36

75

JAMA Oncology

@JAMAOnc

2 years

This review aims to highlight the current understanding of the association of the gut microbiome with the therapeutic response to immunotherapy, chemotherapy, radiotherapy, cancer surgery and more.

1

34

76

JAMA Oncology

@JAMAOnc

7 years

Circulating Cancer DNA - The "Liquid Biopsy"

2

65

75

JAMA Oncology

@JAMAOnc

6 years

How quickly have #immunecheckpointinhibitors changed #clinicalpractice ? Find out #VisualAbstract #BCSM

1

48

72

JAMA Oncology

@JAMAOnc

6 years

This study examines recent original research articles in leading oncology journals to evaluate the use of statements about the trend of a P value toward significance to describe statistically nonsignificant results.

2

40

75

JAMA Oncology

@JAMAOnc

5 years

Analysis of multiomics data from Cancer Genome Atlas cohort & results on objective resp rates to immunotherapy in trials of 21 #cancer types shows combo of immune/neoantigen/checkpoint target variables all needed to predict response to PD-1/PD-L1 inhibs

0

37

75

JAMA Oncology

@JAMAOnc

5 years

High-dose, single-fraction stereotactic body radiation therapy ( #SBRT ) to predominantly non-spine painful bone mets assoc’d w higher rates of pain response than conventional multifraction radiotherapy, poss better local control #RadOnc

0

47

75

JAMA Oncology

@JAMAOnc

4 years

Our report on #COVID19 in #cancer patients from #Wuhan highlights increased risk of cancer patients to infection, esp older lung cancer patients, supporting calls to reduce hospital visits for cancer patients @DrMLChua #SARSCoV2

2

48

73

JAMA Oncology

@JAMAOnc

3 months

Among women with a BRCA1 sequence variation, MRI surveillance is associated with reduced breast cancer mortality risk.

2

27

75

JAMA Oncology

@JAMAOnc

5 years

Rand ph2 trial of pembro vs stereotactic body radiation therapy (SBRT) to a lesion before pembro for adv NSCLC shows doubling of resp rate & longer PFS & OS, though non-signif, w SBRT; main diff in PD-L1 neg tumors #LCSM #RadOnc

0

35

73

JAMA Oncology

@JAMAOnc

2 months

This narrative review summarizes the literature supporting the use of PARP inhibitors for breast cancer treatment, as well as potential future research directions.

0

29

71

JAMA Oncology

@JAMAOnc

7 years

Circulating Cancer DNA - The "Liquid Biopsy"

0

62

70

JAMA Oncology

@JAMAOnc

4 years

Review of 59 publications w 5655 pts who underwent #SABR for #spinal metastases shows spinal SABR was assoc’d w 1 yr local control of 80-90% in de novo setting, >80% if post-op, >65% if re-irradiating. Vertebral compression Fx main risk (10-15%) #RadOnc

1

35

74

JAMA Oncology

@JAMAOnc

7 years

Chimeric antigen receptor (CAR) T-cell therapy for #cancer : an explanation for patients.

0

58

71

JAMA Oncology

@JAMAOnc

3 years

Modern 4-drug combination therapy (carfilzomib-lenalidomide-dexamethasone-daratumumab) is safe, well-tolerated & offers high rates of MRD negativity by itself (ie, in the absence of autologous transplant) in pts w/newly diagnosed multiple myeloma #MMSM

Carfilzomib-Lenalidomide-Dexamethasone-Daratumumab Combination Therapy for Newly Diagnosed Multiple...

This nonrandomized clinical trial assesses the safety and effectiveness of carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for patients with newly diagnosed multiple myeloma,...

jamanetwork.com

1

23

69

JAMA Oncology

@JAMAOnc

7 years

#Cancer -related fatigue more effectively treated by exercise & psychological interventions than by medications.

3

108

73

JAMA Oncology

@JAMAOnc

3 years

PORT-C is a phase Ⅲ randomized study that assessed the role of post-operative radiation therapy (PORT) in pts with pⅢA-N2 NSCLC after complete resection & adjuvant chemo. The results showed PORT failed to improve disease-free or overall survival #LCSM

3

32

71

JAMA Oncology

@JAMAOnc

3 years

STAMPEDE M1|RT exploratory analysis by bone metastasis counts shows that the survival benefit from prostate RT gradually diminishes with increasing bone metastasis number and is most pronounced up to 3 bone metastases @Prof_Nick_James @PCaParker @mattsydes

0

28

72

JAMA Oncology

@JAMAOnc

5 years

0

31

71

JAMA Oncology

@JAMAOnc

5 years

Chimeric Antigen Receptor (CAR) T-Cell Therapy

CAR T-cell therapy uses the patient’s own immune cells to personalize cancer immunotherapy.

jamanetwork.com

2

32

70

JAMA Oncology

@JAMAOnc

6 years

Pro-inflammatory diet, including alcohol, significantly assoc’d w higher rates of #ColonCancer in men > women, particularly in overweight/obese men & lean women. #GICSM #CRCSM

1

58

67

JAMA Oncology

@JAMAOnc

5 years

Analysis of results from database of 47,721 pts w/different cancers shows variable prevalence of DNA polymerase epsilon (POLE) & delta 1 (POLD1) mut’ns that correlates w/overall survival in pts who received immune checkpoint inhibitor therapy

0

35

70

JAMA Oncology

@JAMAOnc

9 months

Stereoablative body radiation (SABR) individualized by dose & fractionation based on tumor size, location, & histologic characteristics was associated w/ overall excellent tumor control & a low rate of toxic effects. #RadOnc #LCSM

0

34

70

JAMA Oncology

@JAMAOnc

7 years

Febrile Neutropenia

0

50

66

JAMA Oncology

@JAMAOnc

4 years

Nausea and vomiting, ind of chemo, can be very problematic for patients with advanced cancer. A small, randomized, placebo-controlled, double-blinded clinical trial supports that olanzapine substantially improves such nausea and vomiting #VisualAbstract

0

31

68

JAMA Oncology

@JAMAOnc

1 year

Phase 3 rand trial of spinal radiosurgery vs. conventional external beam radiation therapy for pts w/spinal metastases showed radiosurgery did not significantly improve pain response at 3mo but showed feasibility that makes it widely used today. #RadOnc

4

29

68

JAMA Oncology

@JAMAOnc

1 month

The 10-year interval between colonoscopy screenings for colorectal cancer (CRC) could be extended to 15 years in patients with no family history of CRC and negative findings on their first colonoscopy, finds matched cohort study.

2

19

66

JAMA Oncology

@JAMAOnc

6 years

Meta-analysis of 5 trials, over 3000 pts w/prev treated adv NSCLC reveals clin & molecular features assoc’d w/benefit from PD-(L)1 immune checkpoint inhib monotherapy v. docetaxel; EGFR mut+ pts derive no benefit, KRAS mut+ pt do #LCSM #immunotherapy

0

60

65

JAMA Oncology

@JAMAOnc

2 months

In patients with early-stage triple-negative breast cancer treated with locoregional therapy only, higher levels of tumor-infiltrating lymphocytes in breast cancer tissue were associated with improved survival.

2

20

66

JAMA Oncology

@JAMAOnc

5 years

Machine learning applied to develop & train an algorithmic classifier of primary cancer of origin from genomic features shows ability to classify ~75% of tumors, w same results from plasma

0

38

66

JAMA Oncology

@JAMAOnc

7 years

Febrile Neutropenia

0

36

63

JAMA Oncology

@JAMAOnc

1 year

Randomized trial of intermittent hormone therapy +/- radiation to oligometastatic sites of #prostatecancer shows significantly improved PFS & assoc time off hormone therapy & w/normal testosterone from combination. #RadOnc #PCSM #GUCSM

0

32

64

JAMA Oncology

@JAMAOnc

4 years

1

27

62

JAMA Oncology

@JAMAOnc

9 months

Could ChatGPT amplify cancer treatment misinformation? This study found that 1/3 of its recommendations are non-concordant with NCCN guidelines. Clinicians should advise patients of ChatGPT limitations. @dbittermanmd @brighamresearch @Bos_CHIP

Use of Artificial Intelligence Chatbots for Cancer Treatment Information

This survey study examines the performance of a large language model chatbot in providing cancer treatment recommendations that are concordant with National Comprehensive Cancer Network guidelines.

jamanetwork.com

3

36

64